NCT06322563 2024-03-21
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
Clinical Trials
207 trialsNCT06280690 2024-02-29
SGM-T1
Leiden University Medical Center
Phase 2 Unknown
NCT04096417 2024-02-21
Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Academic and Community Cancer Research United
Phase 2 Unknown
NCT03924466 2024-02-16
VUBAR
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT05933980 2024-02-06
REGOTORICOX
Sun Yat-sen University
Phase 2 Unknown
NCT05291156 2024-02-01
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
University of Campania Luigi Vanvitelli
Phase 2 Unknown
NCT06231017 2024-01-30
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05435313 2024-01-17
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
Fudan University
Phase 2 Unknown
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT06134765 2023-11-18
Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04034459 2023-11-14
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT04310176 2023-11-13
REVOLUTION
National Cancer Institute, Naples
Phase 2 Unknown
NCT06118047 2023-11-07
COSTIC
Sun Yat-sen University
Phase 2 Unknown
NCT06120127 2023-11-07
IMPROVE
Fudan University
Phase 2 Unknown
NCT06089330 2023-10-18
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Unknown
NCT06060704 2023-10-11
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04033107 2023-09-28
High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
Zhongnan Hospital
Phase 2 Unknown
NCT06039202 2023-09-15
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Holy Stone Healthcare Co., Ltd
Phase 2 Unknown
NCT04659382 2023-08-18
SIRTCI
Federation Francophone de Cancerologie Digestive
Phase 2 Unknown
NCT05669521 2023-08-14
Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690
Tosk, Inc.
Phase 2 Unknown
NCT04724239 2023-08-01
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT05871333 2023-07-19
Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients
Ain Shams University
Phase 2 Unknown
NCT04653480 2023-07-17
Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
Zhejiang University
Phase 2 Unknown
NCT05913570 2023-06-22
MSI-H/dMMR
Henan Cancer Hospital
Phase 2 Unknown
NCT03073694 2023-06-09
Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis
University of Kansas Medical Center
Phase 2 Unknown
NCT05894837 2023-06-08
Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05233332 2023-05-31
mCRC
Shanghai Kechow Pharma, Inc.
Phase 2 Unknown
NCT05527301 2023-05-25
HEM1036 Phase 2 Study in Low Anterior Resection Syndrome
HEM Pharma Inc.
Phase 2 Unknown
NCT05799820 2023-05-25
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT05382741 2023-05-17
VIVA
Ospedale Policlinico San Martino
Phase 2 Unknown
NCT05799443 2023-04-05
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05797883 2023-04-04
FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
China Medical University, China
Phase 2 Unknown
NCT05143099 2023-03-28
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT01628211 2023-03-24
HIPEC
National Cancer Institute, Naples
Phase 2 Unknown
NCT01801904 2023-03-24
PACER
National Cancer Institute, Naples
Phase 2 Unknown
NCT04194359 2023-03-17
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT03803436 2023-03-16
COLT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT05755685 2023-03-06
Hyperthermic Intraperitoneal Treatment of rmhTNF for CRCPM: Phase II Clinical Trial
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05480280 2023-02-28
FIND
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT05201612 2023-02-24
PEMBROLA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Unknown
NCT05684211 2023-02-01
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd.
Phase 2 Unknown
NCT05453825 2023-01-31
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
OncXerna Theraputics, Inc.
Phase 2 Unknown
NCT05659290 2023-01-06
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT05634590 2022-12-02
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
Fudan University
Phase 2 Unknown
NCT05372198 2022-11-09
Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line
Hubei Cancer Hospital
Phase 2 Unknown
NCT05004441 2022-10-26
Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer
Zhongnan Hospital
Phase 2 Unknown
NCT05493683 2022-10-21
Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT02633098 2022-10-12
NeoART
St George's, University of London
Phase 2 Unknown
NCT05551247 2022-09-22
Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT04398446 2022-09-01
Coala-T-CBD
Main Line Health
Phase 2 Unknown